Intrinsiqq
Abbott Laboratories logo

Abbott Laboratories Quality Score

ABT

⊜ Compare
Quality25

Weak across most dimensions. This doesn't mean avoid, but the burden of proof is on the bull case.

Broad-market heuristics · Not a buy/sell signal

Valuation and growth

Earnings Multiple
40/100
32.4x

Above 30x, priced for sustained outperformance

Cash Flow Multiple
60/100
27.1x

25–30x, paying up for cash generation

Revenue Growth
0/100
0.8%

Below 2%, essentially flat

Cash Flow Growth
0/100
-1.4%

Below 2%, essentially flat

Business Quality & Capital Allocation

Share Dilution
80/100
-1.0%

Roughly flat, no meaningful dilution

Margin Trend
0/100
-2.1pp

Contracted >2pp, margin pressure

Capital Structure
0/100
$26.75B

Net debt/FCF of 3.6x, high leverage

2022
$10.2B
$17.9B
2023
$7.28B
$15.9B
2024
$7.97B
$15.3B
2025
$8.94B
$14.1B
TTM
$7.29B
$34.0B
CashDebt
Return on Capital
40/100
8.3%

8–10%, clearing the bar

Customize WeightsPremiumUpgrade

Abbott Laboratories (ABT) quality: score, margins and returns

Abbott Laboratories (ABT) scores 25/100 on Intrinsiqq's quality score (a lower-quality business), a weighted blend of 8 metrics each scored 0 to 100, on 17.1% operating margins and 8.3% ROIC. Every metric is computed from SEC filings; this is analysis, not investment advice.

Frequently asked

Is Abbott Laboratories (ABT) a high-quality business?+

Abbott Laboratories scores 25 out of 100 on Intrinsiqq's quality score, a weighted blend of 8 metrics each scored 0 to 100, which rates it a lower-quality business on these measures. Recent figures include a 17.1% operating margin and a 8.3% return on invested capital. Quality and price are separate questions: even a great business can be a poor investment if you overpay, so read this score alongside the valuation. The metric-by-metric breakdown is on this scorecard.

What does Abbott Laboratories's quality score measure?+

Intrinsiqq's quality score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, change in share count, and balance-sheet strength, each computed from ABT's SEC filings rather than opinion or sentiment. A higher score means a more durable, capital-efficient business; it is not a buy or sell signal. Open each metric on this page to see exactly where Abbott Laboratories scores well and where it falls behind.

What is Abbott Laboratories's return on invested capital (ROIC)?+

Abbott Laboratories earns about 8.3% on its invested capital, which is modest. ROIC measures how much profit a company generates per dollar put to work; sustained ROIC above its cost of capital is one of the clearest signs of a real competitive moat. Compare it to ABT's margins and growth on this scorecard to judge durability.

How profitable is Abbott Laboratories?+

Abbott Laboratories runs an operating margin of about 17.1% and a net margin of about 13.9%. Revenue has grown at roughly 5.1% a year recently. High, stable margins usually point to pricing power and operating discipline. Margins are most telling next to growth and returns on capital, all of which feed this quality score. This is analysis from SEC filings, not investment advice.

How the market compares: US profitability statistics

SourceQuality score computed from the 10-Q filed 29 Apr 2026, covering the period ending 31 Mar 2026, as reported to the SEC. Data last refreshed 28 Sept 2026. How this is calculated.

Fiscal year ends Dec. Sector medians are approximate S&P 500 benchmarks and update periodically. Checks use broad-market heuristics, so sector norms may differ, and the valuation checks are more cyclical than the quality checks.

Peers

Pharmaceutical Preparations · Pick stocks to compare with ABT

CompareIntrinsic value
BMYBristol-Myers Squibb Company
$64.20+4.04%61
PFEPfizer Inc.
$30.79+2.63%30
ABBVAbbVie Inc.
$294.83+3.09%49
MRKMerck & Co., Inc.
$150.36+3.93%41
UPCUniverse Pharmaceuticals Inc.
$1.47-1.34%39
TEVATeva Pharmaceutical Industries Ltd
$42.13+0.52%46
REGNRegeneron Pharmaceuticals, Inc.
$930.67-4.39%54
VTRSViatris Inc.
$19.22+1.59%24

Held by ETFs

ABT is in 336 US ETFs. The largest of them, with ABT's weight in each:

Spot a number that looks wrong? Check it in ABT's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing ABT

Create a free account and get 14 days of Premium: every stock and every tool.

  • Unlimited stocks
  • Stock screener
  • Portfolio tracker
  • Editable DCF
  • Compare side by side
  • Unlimited alerts

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.

SectorsPrivacyTerms© 2026 Intrinsiqq

Not financial advice. Analytical data for research only.

Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.